Melissa Seymour
Known title: EVP, Global QualityCIK: 0002032089
Associated companies
Transaction History
| LLY | ▼ Sell | Gift | 12 | $0 | 9/9/2026 | View on chart |
| LLY | ▲ Buy | Option Exercise | 981 | $0 | 8/1/2026 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 439 | $504K | 8/1/2026 | View on chart |
| LLY | ▼ Sell | Gift | 17 | $0 | 9/22/2025 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 427 | $316K | 8/1/2025 | View on chart |
| LLY | ▲ Buy | Option Exercise | 952 | $0 | 8/1/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill
The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.